Qiagen NV (QGEN)

26.68
NASDAQ : Services
Prev Close 26.55
Day Low/High 26.39 / 26.83
52 Wk Low/High 19.94 / 28.53
Avg Volume 1.12M
Exchange NASDAQ
Shares Outstanding 234.00M
Market Cap 6.21B
EPS 0.50
P/E Ratio 49.17
Div & Yield N.A. (N.A)

Latest News

3 Diversified Services Stocks Nudging The Industry Higher

3 Diversified Services Stocks Nudging The Industry Higher

TheStreet highlights 3 stocks pushing the diversified services industry higher today.

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Qiagen (QGEN) Stock Soars as Q2 Results Surpass Expectations

Qiagen (QGEN) stock is jumping on Friday morning after the company posted earnings and revenue that topped analysts’ projections for the 2016 second quarter.

Watch Out: Barbarians At The Gate For Qiagen (QGEN)

Watch Out: Barbarians At The Gate For Qiagen (QGEN)

Trade-Ideas LLC identified Qiagen (QGEN) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

QIAGEN Launches

QIAGEN Launches "Digital NGS" Solutions With Unique Molecular Index Technology To Reliably Detect All Genetic Variation

QIAseq Targeted NGS panels deliver highly sensitive, unbiased and accurate NGS insights

Buy These 5 Stocks This Week for Breakout Gains

Buy These 5 Stocks This Week for Breakout Gains

These five technical setups are showing solid upside potential right now.

QIAGEN Announces Successful Completion Of Tender Offer For Shares In Exiqon

QIAGEN Announces Successful Completion Of Tender Offer For Shares In Exiqon

Transaction will enhance leadership position in RNA solutions from Sample to Insight

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

Ever hear of space congestion, Bots or liquid biopsy? The phrases are part of a group of 21 investment buzzwords identified by Goldman Sachs in its annual buzzword report.

QIAGEN Joins Consortium To Map Microbial Genomes In 54 Cities

QIAGEN Joins Consortium To Map Microbial Genomes In 54 Cities

Project that measured pathogens in New York City subways goes global this summer

QIAGEN Launches QIAsure Methylation Test To Determine Cervical Cancer Risk

QIAGEN Launches QIAsure Methylation Test To Determine Cervical Cancer Risk

New follow-up assay helps stratify patients with transforming HPV infections

QIAGEN Changes Offer Conditions For Acquisition Of Shares In Exiqon A/S

QIAGEN Changes Offer Conditions For Acquisition Of Shares In Exiqon A/S

Acceptance rate lowered to 89.20% of share capital and voting rights to reflect possible effect of warrants

QIAGEN Announces Second Offer Extension For The Acquisition Of Shares In Exiqon A/S

QIAGEN Announces Second Offer Extension For The Acquisition Of Shares In Exiqon A/S

Offer for DKK 18 per share remains valid until 20 June 2016

QIAGEN Forms Lung Cancer Expert Alliance

QIAGEN Forms Lung Cancer Expert Alliance

Key opinion leaders' expertise to guide design of new gene panels for GeneReader NGS

QIAGEN Launches Liquid Biopsy Workflow For GeneReader NGS System

QIAGEN Launches Liquid Biopsy Workflow For GeneReader NGS System

Actionable Insights Tumor Panel enables monitoring of cancer biomarkers from plasma samples

QIAGEN Integrates Quality Control Tools Into GeneReader NGS System

QIAGEN Integrates Quality Control Tools Into GeneReader NGS System

Reference data set from Horizon affirms proven accuracy of GeneReader workflow

QIAGEN Partners To Develop Predictive Tests In Oncology

QIAGEN Partners To Develop Predictive Tests In Oncology

Collaboration with Therawis addresses unmet need to guide clinical decisions in breast cancer

Qiagen (QGEN) Weak On High Volume

Qiagen (QGEN) Weak On High Volume

Trade-Ideas LLC identified Qiagen (QGEN) as a weak on high relative volume candidate

QIAGEN Extends Tender Offer Period For Acquisition Of Exiqon A/S

QIAGEN Extends Tender Offer Period For Acquisition Of Exiqon A/S

Offer for DKK 18 per share remains valid until 2 June 2016

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARTX, BSX, CBL, ESRT, GV, KRA, LDOS, NNBR, UTX Downgrades: BEN, CHU, DSPG, DX, NUVA, PNRG, QGEN, WBC, WRE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

QIAGEN Launches Streamlined Bioinformatics For RNA Sequencing Of Liquid Biopsies

QIAGEN Launches Streamlined Bioinformatics For RNA Sequencing Of Liquid Biopsies

RNA-seq Explorer Solution generates clear insights for cancer 'omics' analyses

QIAGEN Partners To Develop Novel Companion Diagnostic In Lung Cancer

QIAGEN Partners To Develop Novel Companion Diagnostic In Lung Cancer

Collaboration with Mirati Therapeutics targets MET gene mutations to personalize treatment

QIAGEN's GeneReader NGS System Wins International Design Distinction

QIAGEN's GeneReader NGS System Wins International Design Distinction

First truly end-to-end solution for next-generation sequencing receives Red Dot award